ALPS Medical Breakthroughs ETF (SBIO)
The ALPS Medical Breakthroughs ETF (ticker SBIO) is an actively managed fund that invests in a portfolio of companies involved in scientific and medical advancement — from biotechnology startups to established medical device firms to diagnostics and drug-discovery platforms. It represents a bet on the idea that concentrated exposure to innovation-driven healthcare names will outpace broad-market returns.
The investment premise
Thematic investing — buying a concentrated set of companies riding a particular mega-trend — has become a major industry niche. SBIO embodies this approach by focusing on healthcare and life-science companies selected for their involvement in “breakthroughs.” The fund’s managers define breakthroughs to include novel drug discovery, next-generation diagnostics, precision medicine, advanced surgical techniques, genomics, and other areas where scientific progress could yield new treatments or reshape clinical practice.
The intuition is straightforward: innovation in medicine is accelerating, regulatory pathways are becoming more defined, and the firms that pioneer new treatments or technologies will see faster growth and higher valuations than the broader market. By concentrating on those companies rather than holding the entire healthcare sector, an investor can gain outsized exposure to this tail of winners.
Whether that intuition holds depends entirely on the managers’ skill at identifying which companies will actually achieve breakthroughs and which will burn through capital and fail — a notoriously hard prediction problem.
What goes inside
A typical SBIO portfolio might hold 25 to 40 companies across three rough tiers. The first is early-stage public biotech firms — companies with one or two drugs in development, meaningful cash burn, and clinical-trial risk that dominates the stock’s near-term behaviour. The second is mid-stage companies — those with marketed products and a pipeline behind them, earning revenue but still executing on the next phase of growth. The third includes larger, established medtech and healthcare-services names whose earnings are more predictable but whose exposure to breakthrough trends is genuine (for instance, a hospital operator investing in robotic surgery, or a diagnostics company moving into precision pathology).
The fund rebalances quarterly, which means holdings are not fixed. The list of companies SBIO holds will shift as therapies advance, fail, or are acquired; as cash positions deplete; or as managers spot new entrants whose work aligns with the breakthrough theme.
The character of the holdings
The typical SBIO holding is higher volatility than the healthcare sector as a whole, and far higher volatility than large-cap stocks. Clinical-trial announcements, FDA decisions, and competitive moves cause wild single-day swings. Many holdings have no earnings — they burn cash while their drugs wind through the pipeline — so stock prices rest on narrative and momentum as much as fundamentals. That illiquidity and volatility are features, not bugs, from the fund’s perspective: they are what create the alpha opportunity (if breakthroughs are identified correctly, the upside is commensurately larger).
It also means that SBIO is not a core-portfolio position. It is a satellite bet — something you own alongside a broad equity base if you believe in healthcare innovation and have stomach for drawdowns of 30 or 40 percent during extended biotech winter.
The cost structure and trading
SBIO is an actively managed fund, which means it charges higher annual fees than a passive index-tracking biotech ETF would. The expense ratio reflects the research, portfolio construction, and active rebalancing that the managers perform. Because the holdings are often small-cap and illiquid, turnover can be high, and some of the underlying costs of trading (bid-ask spreads, commissions to dealers) feed into the fund’s overall drag on returns.
The fund trades on an exchange like any ETF, which means you can buy or sell shares during market hours at a visible price. That liquidity is real — you are not locked in — but it is important to remember that the underlying companies in the portfolio are often thinly traded. If the entire portfolio had to be liquidated at once, it would take days or weeks and would involve meaningful price concessions.
The concentration risk
By design, SBIO holds a concentrated portfolio of names — not five hundred different companies, but thirty or forty. That concentration is the mechanism by which it achieves outsized exposure to breakthroughs; it is also the mechanism by which a few wrong bets can dominate returns. If two or three of the fund’s largest positions experience setbacks — a trial failure, a regulatory rejection, a management change — the fund’s performance for an entire year can be determined by those events.
This is distinct from diversification risk. An investor in SBIO is explicitly trading away diversification for theme. That is a conscious choice; the risk is not a flaw but a feature of what the fund is designed to do.
What to watch
Anyone holding SBIO should monitor the clinical-development calendar — knowing which companies in the portfolio have trials readout in the coming months — and the regulatory environment. Changes to the FDA’s approval pathways, shifts in reimbursement policy, or new competition from large pharma entering a therapeutic area can reshape the opportunity set overnight.
The portfolio manager’s track record matters more for this fund than for a passive index fund. Do the managers’ picks outperform peers? Do they rotate out of duds quickly or hold onto losers? These are questions answered by looking at the fund’s holding history and comparing its performance to other actively managed biotech or healthcare-innovation ETFs.